SLXN Stock Overview
A biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Silexion Therapeutics Corp Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.33 |
| 52 Week High | US$13.56 |
| 52 Week Low | US$0.21 |
| Beta | 0 |
| 11 Month Change | -0.83% |
| 3 Month Change | -80.86% |
| 1 Year Change | -96.93% |
| 33 Year Change | -96.58% |
| 5 Year Change | n/a |
| Change since IPO | -96.67% |
Recent News & Updates
Recent updates
Shareholder Returns
| SLXN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 35.9% | -7.5% | -1.2% |
| 1Y | -96.9% | 14.1% | 30.4% |
Return vs Industry: SLXN underperformed the US Biotechs industry which returned 14.1% over the past year.
Return vs Market: SLXN underperformed the US Market which returned 30.4% over the past year.
Price Volatility
| SLXN volatility | |
|---|---|
| SLXN Average Weekly Movement | 27.6% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: SLXN's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: SLXN's weekly volatility (28%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | n/a | Ilan Hadar | silexion.com |
Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor.
Silexion Therapeutics Corp Fundamentals Summary
| SLXN fundamental statistics | |
|---|---|
| Market cap | US$1.88m |
| Earnings (TTM) | -US$1.35m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs SLXN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SLXN income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$1.36m |
| Earnings | -US$1.35m |
Last Reported Earnings
Dec 31, 2013
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did SLXN perform over the long term?
See historical performance and comparison